Engine Capital Issues Statement Regarding Announced Sale of UniFirst to Cintas

NEW YORK--(BUSINESS WIRE)-- Engine Capital LP (together with its affiliates, “Engine” or “we”), which owns approximately 3.2% of the outstanding shares of common stock of UniFirst Corporation (NYSE: UNF) (“UniFirst” or the “Company”), today released the following statement on behalf of Managing Partner Arnaud Ajdler regarding the Company’s announced sale to Cintas Corporation (NASDAQ: CTAS):

“This is the right transaction, at the right price, with the right partner. We are pleased with this outcome, which we believe maximizes value for all UniFirst shareholders. Over the past year, including during our recent proxy contest, we have engaged actively with the Company regarding opportunities to unlock value. We believe this engagement ultimately paved the way for the transaction announced today. I would like to thank the UniFirst Board and the Croatti trustees for pursuing a transaction that recognizes the Company’s strategic value. In particular, I want to thank Chairman Joseph Nowicki and independent director Sergio Pupkin for engaging constructively with shareholders during the recent proxy contest, listening to their feedback, and ultimately bringing this transaction to fruition.”

About Engine Capital

Engine Capital LP is a value-oriented special situations fund that invests both actively and passively in companies undergoing change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311475350/en/

For Media:
Longacre Square Partners
Greg Marose / Bela Kirpalani, 646-386-0091
[email protected] / [email protected]

Source: Engine Capital LP

You May Also Be Interested In

• ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
• Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
• Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss